Yuliya Bahdanovich, Author at Integragen

IntegraGen reports €5.6m in revenues for H1 2023 representing 13% decrease compared to H1 2022 and a cash position of €4.3m

Chiffre affaires en croissance pour IntegraGen - Premier semestre 2021

Decline in microbiology sequencing platform activity after a strong contribution in the first half of 2022 in connection with the Covid-19 pandemic. Adjusted for this base effect, growth was 6% over the period. Slight decrease in revenues recognized by the Evry R&D sequencing platform.

Évry, France, Thursday July (…) »

Press releases // 24 April 2023

IntegraGen reports 2022 annual results with a growth of 16% in revenues and a positive EBITDA.

Increase of activities performed on all sequencing platforms Positive EBITDA for the second consecutive year despite inflation impact on reagents Growth outlook confirmed for 2023
Evry, France, april 24th 2023, 6 pm – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), IntegraGen, a company specializing in the decryption of the (…) »

Press releases // 13 January 2023

IntegraGen reports €12.6m in revenues for 2022 representing 16% growth compared to 2021 and a cash position of €4.5m

Growth supported by the high-throughput genomic sequencing laboratory in Evry Continued sequencing activities on platforms operated on behalf of third parties supported by new clinical research projects in oncology
EVRY, FRANCE, FRIDAY JANUARY 13TH 2023, 7.30AM CET – IntegraGen (FR0010908723 – ALINT), an OncoDNA Group company specializing in the decryption of (…) »

Press releases // 18 October 2022

IntegraGen reports strong revenues growth of 35% with profitability improvement

Better profitability despite the inflation Confirmed growth outlook for the 2022 financial year Increase in services provided to platforms operated on behalf of third parties
EVRY, FRANCE, TUESDAY OCTOBER 18TH 2022, 7.30AM – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), IntegraGen, a company specializing in the decryption (…) »

Press releases // 13 July 2022

IntegraGen reports 6.4 M€ in revenues for the first half of 2022 representing 34% growth compared to H1 2021. Cash position of 4.5 M€.

Continued sustained growth associated with the company’s sequencing platform in Évry and long-term contracts Strong revenue growth linked with microbiology sequencing
Evry, France, Wednesday July 13th 2022, 7.30am – IntegraGen (FR0010908723 – ALINT ), an OncoDNA Group company specializing in the decryption of the human genome which performs (…) »

Press releases // 29 April 2022

IntegraGen reports 2021 annual results with a strong growth of 20% in revenue from current operations and a significant profitability improvement

Positive EBITDA and net result Large increase in services delivered for the SeqOIA GCS and the P2M platform operated for Institut Pasteur Limited negative impact from the pandemic along the year Outlook: continued revenues growth for 2022 based on orders book
Évry, France, april 29TH 2022 – 6.00pm (…) »

News // 20 January 2022

IntegraGen and BIOASTER sign a partnership agreement in genomics and transcriptomics

IntegraGen and BIOASTER have been collaborating for several years in the context of genomic and transcriptomic analyses. Driven by a desire to strengthen this relationship further, the two entities have entered into a long-term partnership agreement (Master Research Service Agreement). This agreement will facilitate and accelerate exchanges between (…) »

Page 1/2 1 2 »

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-advertisement	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
vuid	2 years	This domain of this cookie is owned by Vimeo. This cookie is used by vimeo to collect tracking information. It sets a unique ID to embed videos to the website.
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form.

Archives

IntegraGen reports €5.6m in revenues for H1 2023 representing 13% decrease compared to H1 2022 and a cash position of €4.3m

IntegraGen reports 2022 annual results with a growth of 16% in revenues and a positive EBITDA.

IntegraGen reports €12.6m in revenues for 2022 representing 16% growth compared to 2021 and a cash position of €4.5m

IntegraGen reports strong revenues growth of 35% with profitability improvement

IntegraGen reports 6.4 M€ in revenues for the first half of 2022 representing 34% growth compared to H1 2021. Cash position of 4.5 M€.

IntegraGen reports 2021 annual results with a strong growth of 20% in revenue from current operations and a significant profitability improvement

IntegraGen and BIOASTER sign a partnership agreement in genomics and transcriptomics